Skip to main content
. Author manuscript; available in PMC: 2016 Jul 5.
Published in final edited form as: Adv Exp Med Biol. 2016;916:335–369. doi: 10.1007/978-3-319-30654-4_15

Table 1.

Summary of genetic alterations in human ALL, AML, CLL, and CML

Disease Gene activation, fusion,
inactivation or mutations
Translocations Deletions
ALL RB1, WT1, GATA3, CCND2, ETV6,
RUNX1, EZH2,
SUZ12, EED, PHF6, NOTCH1,
FBXW7, PTEN,
NRAS, NF1, JAK1, JAK3, FLT3,
IL7R, CDKN2A/2B,
BCL11B, LEF1, MYC, CDKN1B,
NUP214-ABL1,
TEL-AML1, EML1-ABL1, ETV6-ABL1,
ETV6-JAK2, BCR-ABL1
t(14;21)(q11.2;q22)
t(11;14)(p13;q11)
t(1;14)(p32;q11)
t(1;7)(p32;q34)
t(7;7)(p15;q34)
t(10;11)(p13;q14)
t(11;19)(q23;p13)
t(7;14)(q34;q13)
t(14;20)(q11;p11)
t(6;7)(q23;q34)
t(7;19)(q34;p13)
t(7;11)(q34;p15)
t(7;12)(q34;p12)
t(11;14)(p15;q11)
t(7;9)(q34;q32)
t(7;11)(q34;p13)
inv(7)(p15q34)
inv(14)(q11.2q13)
inv(14)(q13q32.33)
del(1p32)
del(11p13)
del(9q34)
del(9p21)
AML IDH2, NRAS, TP53, KRAS, RUNX1,
NPM1, FLT3,
DNMT3A, IDH1, TET2, CEBPA, WT1,
PTPN11,
KIT, MYST3-NCOA2, AML1-ETO,
NUP98-HOXA9
t(15;17)
t(8;21)(q22;q22)
inv(16)(11q23)
inv(8)(p11q13)
del(5q)
del(7q)
CLL ZMYM3, CHD2, SF3B1, U2AF2,
SFRS1, XPO1,
ATM, TP53, LRP1B, MAPK1,
MYD88, IGHV,
NOTCH1, FBXW7, DDX3X, TLR2, POT1
t(14;18)(q32;q21)
t(14;19)(q32;q13)
t(11;14)(q13;q32)
t(17;18)(p11;q11)
del(11q22-23)
del(17p13)
del(13q14)
CML BCR-ABL1, EVI1, RB1, TP53, CDKN2A,
ETV6-JAK2
t(9;22)(q34;q11)
inv(3)(q21q26)
t(3;21)(q26;q22)
t(15;17)
(q22;q12-21)
IKZF1 Δ3–6

Information summarized from Van Vlierberghe and Ferrando [4], Takeuchi et al. [5] (ALL); Cancer Genome Atlas Research [6] (AML); Wang et al. [7], Martin-Subero et al. [8], Baliakas et al. [9] (CLL); Johansson et al. [10], Rumpold and Webersinke [11], Mullighan et al. [12] (CML)